Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 696 results

Media Release / Dec 06, 2010

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
Media Release / Nov 30, 2010

Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities

Elimination of 1,400 General Medicines field force positions effective January 1 to align organization with changes in portfolio and evolving healthcare market New organizational alignment creates…
Media Release / Nov 30, 2010

Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
Media Release / Nov 17, 2010

New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers

“Stand Together for AD: Strength and Support for Alzheimer’s” at AlzheimersDisease.com empowers caregivers with new resources and tools to help navigate challenges of caring for a loved one with…
Media Release / Nov 17, 2010

New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
Media Release / Oct 21, 2010

Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection

- Review of data from more than 12,000 people in Cystic Fibrosis Foundation's Patient Registry shows 21% mortality reduction in patients treated with TOBI- TOBI is a widely used inhaled antibiotic…
Media Release / Oct 21, 2010

Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
Media Release / Sep 22, 2010

Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression

Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this diseaseGilenya showed superior efficacy by reducing relapses by 52% at…
Media Release / Sep 22, 2010

Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Media Release / Aug 27, 2010

Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure

-- Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine-- Data showed Tekamlo significantly reduced…

‹ Previous page
1
…
62
63
64
65
66
67
68
…
70
› Next page